Tremelimumab
Last Updated: 04/28/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 735 publications
Favorable Response to Chemotherapy with Durvalumab plus Tremelimumab in Two Cases of KRAS G12C-Positive Pulmonary Sarcomatoid Carcinoma: A Case Report.
Journal: Internal medicine (Tokyo, Japan)
Published: March 18, 2026
Systemic immune profiling uncovers divergent mechanisms and predictive biomarkers of response to combination immunotherapies in hepatocellular carcinoma.
Journal: Journal for immunotherapy of cancer
Published: March 16, 2026
The effect of prior transarterial chemoembolization on response to immune checkpoint inhibitor treatment in patients with hepatocellular carcinoma.
Journal: Clinical and molecular hepatology
Published: March 12, 2026
An Effective Case of Radiofrequency Ablation with the Combination of Durvalumab and Tremelimumab Treatment for Hepatocellular Carcinoma: A Case Report.
Journal: Internal medicine (Tokyo, Japan)
Published: February 23, 2026
A case of immune-mediated myocarditis after durvalumab/tremelimumab treatment for unresectable hepatocellular carcinoma.
Journal: Internal medicine (Tokyo, Japan)
Published: February 23, 2026
Exceptional Response to Durvalumab and Tremelimumab in Pancreatic Acinar Cell Carcinoma With Ultramutated Phenotype Associated With a DNA Polymerase-ε Mutation.
Journal: JCO precision oncology
Published: February 13, 2026
Response to 'Letter to the Editor: "Lymphocyte-Monocyte Ratio Predicts Survival in Patients With Unresectable Hepatocellular Carcinoma Treated With Durvalumab Plus Tremelimumab: A Multicenter Analysis"'.
Journal: Hepatology research : the official journal of the Japan Society of Hepatology
Published: February 12, 2026
Outcomes with Single Tremelimumab Regular Interval Durvalumab (STRIDE) for Unresectable Hepatocellular Carcinoma in the US Veterans Administration.
Journal: Cancers
Published: February 05, 2026
Letter to the Editor: "Lymphocyte-Monocyte Ratio Predicts Survival in Patients With Unresectable Hepatocellular Carcinoma Treated With Durvalumab Plus Tremelimumab: A Multicenter Analysis".
Journal: Hepatology research : the official journal of the Japan Society of Hepatology
Published: January 25, 2026
A Case of Simultaneous Resection of Single Lung and Liver Metastases with Combined Immunotherapy after Radical Surgery for Hepatocellular Carcinoma
Journal: Gan to kagaku ryoho. Cancer & chemotherapy
Published: January 17, 2026
Comparative effectiveness of two first-line, ICI-based regimens for advanced HCC: a target trial emulation using an electronic medical record network.
Journal: Frontiers in oncology
Published: December 26, 2025
Last Updated: 04/28/2026